12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Daxas roflumilast regulatory update

FDA accepted a response from Forest Labs to a May complete response letter for Daxas roflumilast to treat chronic obstructive pulmonary disease (COPD). The agency designated the resubmission as a Class 2 response. Forest and...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >